RANKL Inhibitors & Biosimilars
17 drugsAbout RANKL
RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) is a protein crucial for bone remodeling and immune cell function. It activates its receptor, RANK, on target cells, influencing osteoclast differentiation and activity. TNFSF11 is the gene symbol for RANKL.
Human genetic studies provide strong validation for RANKL as a therapeutic target (max score 0.87). Variants are linked to hypothyroidism (0.87) and autosomal recessive osteopetrosis 2 (0.84), suggesting activation may be beneficial. Loss-of-function variants increase risk for some diseases.
RANKL is targeted by 17 FDA-approved drugs, including JUBBONTI, WYOST, and AUKELSO, primarily for oncology indications. Most drugs are biologics (15), with a smaller number of antibodies (2). The first drug, PROLIA, was approved in 2010.
RANKL Genetic Evidence Strong
RANKL has strong genetic support with a max score of 0.87 linked to hypothyroidism.
Strong genetic support suggests that clinical trials targeting RANKL have an increased likelihood of success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 1 traits
- • Strong signal in disorder of visual system, genetic, familial or congenital disease, musculoskeletal or connective tissue disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
20 totalGWAS and other genetic studies link TNFSF11 to 47 diseases.
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for TNFSF11 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top RANKL Drugs
Nine companies have approved drugs targeting RANKL, with Novartis among the top players.
The presence of multiple companies indicates moderate competition, but high barriers to entry due to established biologics.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| WYOST | Novartis | 2024 | 4 |
| XGEVA | Amgen | 2010 | 4 |
| CONEXXENCE | Fresenius Kabi | 2025 | 4 |
| BOMYNTRA | Fresenius Kabi | 2025 | 4 |
| XTRENBO | Hikma | 2025 | 4 |
| BILPREVDA | SHANGHAI HENLIUS BIOTECH | 2025 | 4 |
| BILDYOS | SHANGHAI HENLIUS BIOTECH | 2025 | 4 |
| OSPOMYV | SAMSUNG BIOEPIS CO LTD | 2025 | 4 |
| OSENVELT | CELLTRION INC | 2025 | 4 |
| OZILTUS | AMNEAL PHARMS | 2025 | 4 |
| BOSAYA | BIOCON BIOLOGICS INC | 2025 | 3 |
| ENOBY | Hikma | 2025 | 3 |
| STOBOCLO | CELLTRION INC | 2025 | 3 |
| BONCRESA | AMNEAL PHARMS | 2025 | 3 |
RANKL Drug Modality Landscape
Modalities
Routes of Administration
RANKL requires biologic approaches (biologic (other)), likely due to its structure or location.
The prevalence of biologics suggests an opportunity for small molecule RANKL modulators to enter the market.
📈 Modality Evolution
Antibodies pioneered RANKL targeting (2010), with other biologics entering more recently (2024).
RANKL Clinical Trials 196 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on RANKL. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 37 | 28 | 5 | 4 | 85% |
| Phase 2 | 58 | 36 | 12 | 10 | 75% |
| Phase 3 | 52 | 36 | 9 | 7 | 80% |
| Phase 4 | 49 | 23 | 4 | 21 | 85% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved RANKL drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting RANKL. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
RANKL Drug Approval Timeline (2010 - 2025)
RANKL drug approvals span 16 years, from 2010 to the most recent in 2025.
The continued approval of new RANKL-targeting drugs suggests sustained interest and potential for further market growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 9 companies competing
- • Market share by company
Full Drug Portfolio
- • All 17 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 17-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 111 (25 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on RANKL. A trial counts if an approved drug acting on RANKL is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.